ArticleFrontiers in cardiovascular medicine2026
Clinical practice of cangrelor use in Austrian ACS patients: a real-world multicenter registry.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cangrelor is the only available intravenous P2Y Methods: We performed a retrospective cross-sectional analysis using data from a nationwide Austrian registry including 10 high-volume percutaneous coronary intervention (PCI) centers over a 7-year period. The timing of concomitant antiplatelet and anticoagulant therapy was assessed. Major adverse cardiovascular events (MACE) and bleeding complications occurring during the index hospitalization, for up to 7 days, were recorded. Results: A total of 626 patients were consecutively enrolled over a 7-year period. Cangrelor was administered for a median duration of 2.5 h. Marked inter-center differences were observed in transition strategies and pre-procedural antithrombotic therapy. Overall, 69% of patients received aspirin and heparin alone, whereas 31% also received an oral P2Y Conclusion: This nationwide real-world study highlights considerable variability in the clinical use of Cangrelor and its integration with oral P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.